The Anti-CD326/EpCAM Antibody (Ber-EP4) is a chimeric mouse monoclonal antibody of the IgG1 κ isotype, specifically designed to target human CD326, also known as Epithelial Cell Adhesion Molecule (EpCAM). This antibody has been engineered for high specificity and affinity toward the EpCAM antigen, a cell surface protein predominantly expressed in epithelial tissues and associated with cell signaling, migration, proliferation, and differentiation. It is commonly utilized in research focusing on cancer biology, particularly in studies involving carcinomas where EpCAM is often overexpressed. For accurate isotype control in experimental assays, the use of Mouse IgG1 kappa Isotype Control is recommended to ensure specificity and consistency in results.
The Anti-CD326/EpCAM Antibody (Ber-EP4) is a chimeric mouse monoclonal antibody of the IgG1 κ isotype, specifically designed to target human CD326, also known as Epithelial Cell Adhesion Molecule (EpCAM). This antibody has been engineered for high specificity and affinity toward the EpCAM antigen, a cell surface protein predominantly expressed in epithelial tissues and associated with cell signaling, migration, proliferation, and differentiation. It is commonly utilized in research focusing on cancer biology, particularly in studies involving carcinomas where EpCAM is often overexpressed. For accurate isotype control in experimental assays, the use of Mouse IgG1 kappa Isotype Control is recommended to ensure specificity and consistency in results.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
